الفهرس 
Polycystic Ovary Syndrome (PCOS)Only 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
Anovulation is the most frequent cause of infertility, accounting for 20 to 25% of all infertility cases. Polycystic ovary syndrome (PCOS), which affects 4-7% of women globally, is one of the most frequent causes of anovulatory infertility.
Aim of the Work: The aim of study is to compare the effectiveness of tamoxifen (TMX) versus Letrozole in ovulation induction in women with PCOS.
Patients and Methods: This was a prospective single blinded randomized controlled clinical trial that was conducted at Ain Shams University Maternity Hospital, Infertility Clinic from February, 2021 to June, 2021. 80 women with anovulatory infertility due PCOS were included in this study. The study compared the reproductive outcomes of women with PCOS after administration of the letrozole as an aromatase inhibitor and Tamoxifen. We followed the patients for three consecutive cycles.
Results: This study showed no statistically significant differences regarding sociodemographic data as age, BMI, and type of infertility. There were also no significant differences regarding basal hormonal profile. Ovulation rate, number of follicles, pregnancy rate and endometrial thickness were significantly higher in letrozole group compared to tamoxifen group.
Conclusion: Both letrozole and TMX should be considered as optional therapies for PCOS women with anovulation. In addition, letrozole was superior to TMX in achieving a higher pregnancy and ovulation rate and better endometrial thickness than Tamoxifen.